In recent years, serum uric acid (SUA) as a determinant of cardiovascular (CV) risk has
gained interest. Epidemiological, experimental and clinical data show that patients with …

The role of hyperuricaemia as cardiovascular risk factor has exhaustingly been debated for
decades. While the association of elevated uric acid (UA) levels with increased mortality risk …

Allopurinol lowers blood pressure in adolescents and has other vasoprotective effects.
Whether similar benefits occur in older individuals remains unclear. We hypothesized that …

Introduction Ischaemic heart disease (IHD) is one of the most common causes of death in
the UK and treatment of patients with IHD costs the National Health System (NHS) billions of …

Background Hyperuricemia and gout have been associated with increased cardiovascular
risk. Allopurinol is an effective urate-lowering drug. Whether lowering of urate by allopurinol …

Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant
and independent risk factor for hypertension and cardiovascular diseases, such as ischemic …

Background Previous observational studies that have examined the association of
allopurinol with myocardial infarction (MI) have provided contradictory results. One study …

Hyperuricemia has been shown to be associated with ventricular arrhythmias. However, the
mechanisms remained unknown. We assessed whether different urate-lowering agents can …

Background Serum uric acid (UA) elevation is common in patients with cardiovascular, renal
and metabolic diseases. However, no study to date has analysed the role of UA in Fabry …

Heart failure with reduced ejection fraction (HFrEF) is a common cardiovascular condition
with a significant individual and societal burden. Although it was previously known as a …